Evonik Industries has increased its production capacity for the pharmaceutical amino acid glycine by 50 percent due to rising demand. This was achieved by efficiency gains in the production process. Evonik manufactures the amino acid at its Chinese Nanning site in accordance with the strict requirements of cGMP (current Good Manufacturing Practice) and the European Pharmacopoeia (CEP; Certificate of Suitability of Monographs of the European Pharmacopoeia). Evonik is investing in a new plant in Nanning to expand its portfolio of specialty chemical products by milling and sieving processes. The new qualities are expected to come on the market at the end of the year.
“We’re currently experiencing strong demand for our glycine,” reports Dr. Thomas Hermann, head of the Rexim Product Line. “By increasing our production capacities, we can keep up with this demand and further solidify our excellent market position.”
By upgrading its technologies particularly in the purification process, Evonik has further improved product quality. “We’re now able to provide glycine in all crystalline forms and particle size distributions requested by customers," notes Dr. Jean-Louis Philippe, the responsible marketing manager for the pharmaceutical amino acids.